NASDAQ:AMRS - Amyris Stock Price, Forecast & News

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Shares of Amyris reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.51) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.53) by $0.02. The biotechnology company had revenue of $34.95 million for the quarter, compared to the consensus estimate of $21.60 million. View Amyris' Earnings History.

Amyris is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Amyris.

Amyris updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$150 million, compared to the consensus revenue estimate of $$148.65 million.

2 brokers have issued 12-month price objectives for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 253.2% from the stock's current price. View Analyst Price Targets for Amyris.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

News stories about AMRS stock have been trending somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amyris earned a news impact score of -1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Amyris.

Amyris saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 17,190,000 shares, an increase of 11.7% from the December 31st total of 15,390,000 shares. Based on an average trading volume of 1,060,000 shares, the short-interest ratio is currently 16.2 days. Approximately 31.4% of the company's stock are sold short. View Amyris' Current Options Chain.

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), CVR Energy (CVI), PBF Energy (PBF), World Fuel Services (INT), Delek US (DK), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), REX American Resources (REX), Green Plains (GPRE), Adams Resources & Energy (AE) and Gevo (GEVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Advanced Micro Devices (AMD), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Intel (INTC), General Electric (GE) and Cara Therapeutics (CARA).

Amyris' stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.04%), Traynor Capital Management Inc. (0.03%) and SG Americas Securities LLC (0.02%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

AMRS stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, SG Americas Securities LLC and Traynor Capital Management Inc.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Insider Buying and Selling for Amyris.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $2.69.

Amyris has a market capitalization of $283.80 million and generates $80.42 million in revenue each year. The biotechnology company earns $-230,240,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe.View Additional Information About Amyris.

The official website for Amyris is http://amyris.com/.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]